EPS for Kamada Ltd. (KMDA) Expected At $0.03

April 23, 2018 - By wolcottdaily

Analysts expect Kamada Ltd. (NASDAQ:KMDA) to report $0.03 EPS on May, 15.They anticipate $0.14 EPS change or 127.27 % from last quarter’s $-0.11 EPS. KMDA’s profit would be $1.25M giving it 37.50 P/E if the $0.03 EPS is correct. After having $0.16 EPS previously, Kamada Ltd.’s analysts see -81.25 % EPS growth. The stock decreased 2.17% or $0.1 during the last trading session, reaching $4.5. About 53,091 shares traded or 178.02% up from the average. Kamada Ltd. (NASDAQ:KMDA) has declined 31.39% since April 24, 2017 and is downtrending. It has underperformed by 42.94% the S&P500.

Kamada Ltd. (NASDAQ:KMDA) Ratings Coverage

Among 2 analysts covering Kamada (NASDAQ:KMDA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kamada had 2 analyst reports since February 2, 2018 according to SRatingsIntel. The stock of Kamada Ltd. (NASDAQ:KMDA) earned “Buy” rating by H.C. Wainwright on Thursday, February 8.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. The company has market cap of $188.20 million. It operates through two divisions, Proprietary Products and Distribution. It has a 25 P/E ratio. The company??s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency ; Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma.

Kamada Ltd. (NASDAQ:KMDA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.